Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis
- 396 Downloads
Hormonal treatment of endometriosis is often continued for long periods and has the potential to affect many essential metabolic processes. The current study aimed to determine the effects and safety of high-dose dienogest as a medical endometriosis therapy.
The effects and safety of high-dose dienogest, 20–30 mg/day for 24 weeks, were examined in 21 women aged 18–52 years with laparoscopically and histologically proven endometriosis stage I–IV (according to revised American Society of Reproductive Medicine criteria). At baseline and week 24, sera were obtained and stored at −20°C prior to analysis.
The study showed no clinically significant effect of high-dose dienogest on thyroid or adrenal function, electrolyte balance or haematopoiesis. High-dose dienogest therapy also had no appreciable effects on glucose and lipid metabolism, liver enzymes or haemostasis. For instance, although dienogest mediated small increases in the haemostatic variables prothrombin fragment 1 + 2, antithrombin III and protein C, final levels (at week 24) remained within normal reference ranges for these parameters. The exception was the HDL-3 cholesterol concentration at week 24 (0.97 mmol/l), which increased beyond the normal range of 0.28–0.64 mmol/l.
This investigation yielded a unique dataset on the safety of high-dose dienogest in endometriosis stage I–IV. High-dose dienogest (20–30 mg/day) had little influence upon all the parameters measured. It is therefore likely that lower doses of dienogest would have similarly neutral safety effects: an important consideration in the use of dienogest for the treatment of endometriosis.
KeywordsEndometriosis Dienogest Progestogen Lipids Laboratory parameters Haemostasis
Conflict of interest statement
The authors declare that they have no conflict of interest.
- 3.Mahutte NG, Kayisli U, Arici A (2005) Endometriosis is an inflammatory disease. In: Olive D (ed) Endometriosis in clinical practice. Taylor and Francis, Oxford, pp 79–88Google Scholar
- 7.Oettel M, Carol W, Elger W (1995) A 19-norprogestin without 17β-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 31:517–536Google Scholar
- 11.Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H et al (2009) Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertil Steril 91:675–681CrossRefPubMedGoogle Scholar
- 13.Momoeda M, Taketani Y (2007) Randomized double-blind, multicentre, parallel-group dose–response study of dienogest in patients with endometriosis. Jpn Pharmacol Ther 35:769–783Google Scholar
- 30.Hughes JK, Mendelsohn D (1999) Serum lipoprotein (a) levels in ‘normal’ individuals, those with familial hypercholesterolaemia, and those with coronary artery disease. S Afr Med J 78:567–570Google Scholar